Skip to main content

Stereotactic Body Radiation Therapy in Treating Patients with Metastatic Cancer with Limited Progression on Immune Checkpoint Inhibitors

Trial Status: Active

This phase II trial studies how well stereotactic body radiation therapy works in treating patients with cancer that has spread to other places in the body with limited progression while on immune checkpoint blockade. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue.

Inclusion Criteria

  • Subjects must have signed and dated an Institutional Review Board (IRB) approved written informed consent form in accordance with regulatory and institutional guidelines
  • Subjects must be willing and able to comply with scheduled visits, treatment schedule, laboratory testing, and other study obligations
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2
  • Histologically confirmed metastatic cancer of any histology for which there is an Food and Drug Administration (FDA) indication for an immune checkpoint inhibitor including melanoma, lung, bladder, renal and head/neck cancers
  • Patient has been receiving treatment with an immune checkpoint inhibitor including but not limited to ipilimumab, nivolumab, avelumab, durvalumab, pembrolizumab, atezolizumab, and tremelimumab for at least 2 months. A combination of these therapies is also permitted. No max prior lines of therapy
  • Patient has evidence of limited progression (up to 5 lesions either new or increase in at least 25% in the cross-sectional diameter of a known lesion) on most recent systemic imaging as determined by the treating physician. Patients with greater than 5 lesions can be included after discussion with the study investigators
  • Patient must be eligible to continue to receive an immune checkpoint inhibitor after radiotherapy
  • Subjects must have at least two lesions: * One lesion must be safely amenable to irradiation in the opinion of the treating radiation oncologist. This can be a lesion that was previously irradiated if it is deemed appropriate by the treating physician and principal investigator. Standard Memorial Sloan Kettering Cancer Center (MSKCC) re-irradiation dose constraints must be met. * At least one, not-to-be-irradiated lesion measurable by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST 1.1 criteria
  • Prior palliative or curative radiotherapy must be completed at least 14 days prior to treatment
  • Immunosuppressive doses of systemic medication, such as steroids or absorbed topical steroids (doses > 10 mg/day prednisone or equivalent) must be discontinued at least 14 days prior to radiotherapy administration
  • Women of childbearing potential must have a negative serum within 7 days prior to treatment, or urine pregnancy test (within 24 hours) (minimum sensitivity 25 IU/L or equivalent units of HCG). Women of childbearing potential must agree to follow instructions for method(s) of contraception from time of enrollment for the duration of treatment
  • Men who are sexually active with women of childbearing potential (WOCBP) must use any contraceptive method with a failure rate of less than 1% per year. *Notes: ** Women who are not of childbearing potential i.e., who are postmenopausal or surgically sterile as well as azoospermia men do not require contraception. ** Azoospermic males, and women of childbearing potential who are continuously not heterosexually active, are exempt from contraceptive requirements. However, they still must have a pregnancy test

Exclusion Criteria

  • Active brain metastases (untreated brain metastases or growth on imaging as defined below) or leptomeningeal disease are not allowed. Subjects with brain metastases are eligible if these have been treated and there is no MRI (or CT if MRI contraindicated) evidence of progression for at least 8 weeks after treatment for these metastases is complete and within 28 days prior to first study treatment
  • Any medical disorder that, in the opinion of the investigator, might increase the risk associated with study participation or interferes with the interpretation of study results
  • Prior active malignancy within the previous 3 years except for locally curable cancers such as basal or squamous skin cancer, superficial bladder, low risk prostate cancer, breast, or cervix cancer. If other prior malignancy was active within prior 3 years, enrollment requires approval of a principal investigator
  • Patients should be excluded if they have an active, known or suspected autoimmune disease. Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger
  • Subjects requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents for greater than 5 days) or other immunosuppressive medications within 14 days of study drug administration should be excluded. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
  • Treatment with any other chemotherapy, radiation therapy, biologics for cancer, or investigational therapy concurrently or within 14 days of enrollment
  • History of allergy to checkpoint inhibitors
  • History of severe hypersensitivity reaction to any monoclonal antibody
  • Women must not be breastfeeding


Hartford Hospital
Status: ACTIVE
Contact: Charles E. Rutter
Phone: 860-972-2803

New Jersey

Basking Ridge
Memorial Sloan Kettering Basking Ridge
Status: ACTIVE
Contact: Yoshiya (Josh) Yamada
Phone: 212-639-2950
Memorial Sloan Kettering Monmouth
Status: ACTIVE
Contact: Yoshiya (Josh) Yamada
Phone: 212-639-2950
Memorial Sloan Kettering Bergen
Status: ACTIVE
Contact: Yoshiya (Josh) Yamada
Phone: 212-639-2950

New York

Memorial Sloan Kettering Commack
Status: ACTIVE
Contact: Yoshiya (Josh) Yamada
Phone: 212-639-2950
New York
Memorial Sloan Kettering Cancer Center
Status: ACTIVE
Contact: Yoshiya (Josh) Yamada
Phone: 212-639-2950
Memorial Sloan Kettering Nassau
Status: ACTIVE
Contact: Yoshiya (Josh) Yamada
Phone: 212-639-2950
West Harrison
Memorial Sloan Kettering Westchester
Status: ACTIVE
Contact: Yoshiya (Josh) Yamada
Phone: 212-639-2950


Lehigh Valley Hospital-Cedar Crest
Status: ACTIVE
Contact: Alyson F. McIntosh
Phone: 610-402-0700


I. To evaluate response rate (ORR) as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria for patients receiving immune checkpoint inhibitors and stereotactic body radiation therapy (SBRT).


I. To evaluate ORR rate as defined by immune-related response criteria (irRC) for non-irradiated lesions.

II. To evaluate progression free survival (PFS) and overall survival (OS) in patients receiving radiation.

III. To evaluate duration of response (DOR).

IV. To evaluate treatment-related adverse events (tr-AE) of combined checkpoint blockade and hypofractionated radiotherapy.

V. To evaluate the impact of prior cytotoxic systemic therapy (type of drug[s] and when it was given) on immune response.


I. Evaluation of ORR as define by positron emission tomography (PET)-response criteria.

II. Evaluating correlations of the following factors with response: tumor tissue PDL1 expression via immunohistochemistry (IHC); changes in T-cell receptor repertoire; peripheral blood mononuclear cell composition; peripheral blood immune cell markers activation and expression; soluble biomarkers including cytokines; neo-antigen expression (optional).


Patients undergo stereotactic body radiotherapy over 3 fractions per lesion within 14 days of receiving checkpoint inhibitor in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for up to 2 years.

Trial Phase Phase II

Trial Type Treatment

Lead Organization
Memorial Sloan Kettering Cancer Center

Principal Investigator
Yoshiya (Josh) Yamada

  • Primary ID 18-359
  • Secondary IDs NCI-2018-02287
  • ID NCT03693014